Prospective validation study of a predictive score for operability of recurrent ovarian cancer: The multicenter intergroup study DESKTOP II. A project of the AGO kommission OVAR, AGO study group, NOGGO, AGO-Austria, and MITO

International Journal of Gynecological Cancer

Volumn 21, Issue 2, 2011, Pages 289-295

  Harter, Philipp ^a,b   Sehouli, Jalid ^c   Reuss, Alexander ^d   Hasenburg, Annette ^e   Scambia, Giovanni ^f   Cibula, David ^g   Mahner, Sven ^h   Vergote, Ignace ⁱ   Reinthaller, Alexander ^j   Burges, Alexander ^k   Hanker, Lars ^l   Pölcher, Martin ^m   Kurzeder, Christian ⁿ   Canzler, Ulrich ^o   Petry, Karl Ulrich ^p   Obermair, Andreas ^q   Petru, Edgar ^r   Schmalfeldt, Barbara ^k   Lorusso, Domenica ^e   Du Bois, Andreas ^a,b  

^a DR HORST SCHMIDT KLINIKEN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

^f CATHOLIC UNIVERSITY   (Italy)

^g CHARLES UNIVERSITY   (Czech Republic)

^h UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j UNIVERSITY OF VIENNA   (Austria)

^k UNIVERSITY OF MUNICH   (Germany)

^l GOETHE UNIVERSITY   (Germany)

^m UNIVERSITY OF BONN   (Germany)

ⁿ UNIVERSITY OF ULM   (Germany)

^o DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^p City Hospital Wolfsburg   (Germany)

^q ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^r UNIVERSITY OF GRAZ   (Austria)

more..

Author keywords

AGO score; Recurrent ovarian cancer; Surgery ovarian cancer

Indexed keywords

PLATINUM;

ADULT; AGED; AGO SCORE; ARTICLE; CANCER SURGERY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; OUTCOME ASSESSMENT; OVARY CANCER; PERIOPERATIVE PERIOD; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; RECURRENT CANCER; RELAPSE; REOPERATION; SCORING SYSTEM; VALIDATION STUDY; VALIDITY;

EID: 79956096959     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31820aaafd     Document Type: Article

References (22)

1. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248-1259. (Pubitemid 34177431)
2. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194-3200. (Pubitemid 46606249)
3. du Bois A, Lück HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320-1329.
4. du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115:1234-1244.
5. Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer. 2000;88:144-153. (Pubitemid 30027690)
6. Gronlund B, Lundvall L, Christensen IJ, et al. Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum. Eur J Surg Oncol. 2005;31:67-73. (Pubitemid 40103927)
7. Jaenicke F, Holscher M, Kuhn W, et al. Radical surgery procedure improves survival time in patients with recurrent ovarian cancer. Cancer. 1992;70:2129-2136.
8. Sehouli J, Richter R, Braicu EI, et al. Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients. J Surg Oncol. 2010;102:656-662.
9. Leitao MM, Kardos S, Barakat RR, et al. Tertiary cytoreduction in patients with recurrent ovarian cancer. Gynecol Oncol. 2004;95:181-185.
10. Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2001;83:504-512. (Pubitemid 33139711)
11. Tay EH, Grant PT, Gebski V, et al. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol. 2002;99:1008-1013. (Pubitemid 34621223)
12. Zang RY, Li ZT, Tang J, et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer. 2004;100:1152-1161. (Pubitemid 38325942)
13. Benedetti Panici P, De Vivo A, Bellati F, et al. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol. 2007;14:1136-1142.
14. Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13:1702-1710. (Pubitemid 44951480)
15. Harter P, Hahmann M, Lueck HJ, et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol. 2009;16:1324-1330.
16. SAS Institute, Inc, Cary, NC.
17. Gerestein CG, Damhuis RAM, Burger CW, et al. Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review. Gynecol Oncol. 2009;114:523-527.
18. Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006;106:1933-1939. (Pubitemid 43673208)
19. Bristow RE, Peiretti M, Gerardi M, et al. Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome. Gynecol Oncol. 2009;114:173-177.
20. Lenhard MS, Burges A, Johnson TR, et al. PET-CT in recurrent ovarian cancer: impact on treatment planning. Anticancer Res. 2008;28:2303-2308.
21. Axtell AE, Lee MH, Bristow RE, et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol. 2007;25: 384-389. (Pubitemid 350002986)
22. Fagotti A, Fanfani F, Rossitto C, et al. A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and staging laparoscopy. Oncology. 2008;75: 152-158.